Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial

Study Questions:

How do the risks of bleeding associated with dabigatran compare at 150 mg versus 110 mg twice daily in the RE-LY trial of patients with atrial fibrillation?